Drug name - Xhance

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8327844 OPTINOSE US INC Nasal delivery method Oct, 2023

(1 year, 5 days from now)

US7975690 OPTINOSE US INC Nasal devices Dec, 2025

(3 years from now)

US10124132 OPTINOSE US INC Nasal delivery Mar, 2027

(4 years from now)

US10076615 OPTINOSE US INC Nasal delivery Jul, 2029

(6 years from now)

US8550073 OPTINOSE US INC Nasal delivery Oct, 2029

(7 years from now)

US8978647 OPTINOSE US INC Nasal delivery Dec, 2030

(8 years from now)

US10252010 OPTINOSE US INC Nasal delivery devices Feb, 2031

(8 years from now)

US11033696 OPTINOSE US INC Nasal delivery devices May, 2033

(10 years from now)

US10179216 OPTINOSE US INC Nasal delivery devices Jul, 2033

(10 years from now)

US10478574 OPTINOSE US INC Nasal administration Nov, 2033

(11 years from now)

US10076614 OPTINOSE US INC Nasal delivery devices Oct, 2034

(12 years from now)

US10300229 OPTINOSE US INC Nasal delivery devices Jul, 2035

(12 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Treatment: Method of delivering fluticasone propionate to a nasal airway

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.093MG SPRAY, METERED;NASAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.